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Abstract
PKR is an interferon(IFN)-induced, serine-threonine protein kinase, which plays a crucial role in IFN’s antiviral and antiproliferative
actions. The three known activators of PKR are dsRNA, heparin, and PACT. PACT activates PKR by direct protein–protein interaction in
response to cellular stress. The human TAR (trans-activating region)-binding protein (TRBP), which is very homologous to PACT, also
interacts with PKR, leading to an inhibition of PKR activity. Since these two highly homologous proteins have opposite effects on PKR,
we examined if they interact with PKR differently by assaying their interaction with various point mutants of PKR. Our results indicate that
TRBP and PACT interact with PKR through the same residues, and no differences were identified in these two interactions. Domain swap
experiments between PACT and TRBP indicated that the inhibitory effects of TRBP on PKR activity are mediated through its carboxy-
terminal residues, which contain TRBP’s third dsRNA-binding motif.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Interferons (IFNs) mediate their antiviral and antiprolif-
erative actions by inducing a number of genes at the tran-
scriptional level (Sen and Lengyel, 1992; Sen and Ranso-
hoff, 1993). PKR is an IFN-induced serine-threonine
protein kinase which is one of the key molecules in IFN’s
cellular actions (Clemens and Elia, 1997; Meurs et al.,
1990). Although the impact of PKR activation has been best
studied on antiviral pathways, PKR has also been shown to
be involved in several cytokine and dsRNA-induced signal-
ing pathways in the inflammatory response (Goh et al.,
2000; Kumar et al., 1997; Williams, 1995, 1999). PKR
activation leads to phosphorylation of its substrate, the 
subunit of the translation initiation factor 2 (eIF2), which
results in a general block in protein synthesis (Colthurst et
al., 1987; Samuel, 1993). Although induced by IFNs, PKR’s
kinase activity stays latent until it is activated by binding to
an activator. One of the best studied activators of PKR is the
dsRNA, which serves a major role in activating PKR during
viral infections (Hovanessian, 1989; Hovanessian et al.,
1987; Katze, 1995, 2002). PKR has been shown to bind to
dsRNAs as short as 11 bp long; however, a perfectly du-
plexed stretch of 50 bp is required for its activation (Manche
et al., 1992). dsRNAs that satisfy these requirements are not
present in uninfected cells. PKR activation in response to a
variety of stress signals other than virus infection is brought
about by PACT, its only known protein activator (Ito et al.,
1999; Patel and Sen, 1998a). Treatment of mammalian cells
with stress agents results in a rapid phosphorylation of
PACT, its increased association with PKR, leading to
PKR’s activation, eIF2 phosphorylation, and subsequent
apoptosis (Patel et al., 2000). Thus, PACT overexpressing
cells exhibit enhanced apoptosis in response to a variety of
stress signals.
PACT’s interaction with PKR occurs through the two
conserved double-stranded RNA binding motifs (dsRBMs)
present at the amino-terminus of PKR (Patel and Sen,
1998a). These motifs are evolutionarily conserved and are
present, often in multiple copies, in RNA-binding proteins
from Escherichia coli to human (Fierro-Monti and
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Mathews, 2000; St Johnston et al., 1992). Although these
motifs were originally shown to be involved in binding to
dsRNA, subsequent work showed their contribution to pro-
tein–protein interactions including dimerization of PKR
(Cosentino et al., 1995; Ortega et al., 1996; Patel and Sen,
1998b; Patel et al., 1995, 1996; Tian and Mathews, 2001).
Within these motifs, distinct basic residues on one side of an
amphipathic helix are essential for interaction with dsRNA.
Several hydrophobic residues on the other side of this am-
phipathic helix are essential for dimerization of PKR but
dispensable for dsRNA binding, thereby indicating that the
dsRNA binding and dimerization properties are independent
of each other (Patel and Sen, 1998b). Although several other
proteins with these motifs also interact with PKR, it is
unclear at present if dsRBMs in all other proteins also
mediate protein–protein interactions in addition to their role
in RNA binding. PACT contains three copies of dsRBM
(M1, M2, and M3) and the two amino-terminal copies
(motifs M1 and M2) mediate its interaction with PKR
(Huang et al., 2002; Peters et al., 2001). The third, carboxy-
terminal copy (Motif M3), lacks conservation of the crucial
residues involved in dsRNA binding and therefore has no
detectable dsRNA binding activity of its own. This motif
plays an essential role in activation of PKR, and deletion
mutants of PACT lacking this third motif can interact effi-
ciently with PKR but are unable to activate its kinase ac-
tivity (Huang et al., 2002; Peters et al., 2001). Thus, the
PKR interaction and activation motifs of PACT are distinct
and nonoverlapping.
TRBP was originally identified and cloned as a gene
encoding human immunodeficiency virus (HIV) trans-acti-
vating Region (TAR)-binding protein (Gatignol et al., 1991;
Park et al., 1994). TRBP belongs to the same family of RNA
binding proteins and similar to PACT, possesses three cop-
ies of dsRBM (St Johnston et al., 1992). TRBP and PACT
share a high degree of homology and both these proteins are
known to interact with PKR (Cosentino et al., 1995; Daher
et al., 2001; Patel and Sen, 1998a). TRBP’s two amino-
terminal dsRBMs interact in an dsRNA-independent man-
ner with PKR’s two dsRBMs, similar to the PACT-PKR
interaction (Daher et al., 2001). Despite having a high de-
gree of homology, these two proteins have opposite effects
on PKR activation. PACT functions as an activator of PKR,
whereas TRBP acts as an inhibitor (Daher et al., 2001; Park
et al., 1994). TRBP overexpression in NIH 3T3 cells has
been shown to lead to malignant transformation due to the
inhibition of PKR activity (Benkirane et al., 1997). It is thus
interesting that two very homologous proteins which inter-
act with PKR through the same domains have opposite
effects on PKR’s activity. We reasoned that although the
two proteins seem to interact through PKR’s dsRBMs, they
may be interacting through different residues within these
domains, which could be studied by assaying interaction of
different point mutants of PKR with both these proteins.
Here, we report the results of these experiments using both
in vitro coimmunoprecipitation and in vivo mammalian
two-hybrid systems.
Results
PACT (PKR activator) and TRBP (PKR inhibitor) both
belong to the same family of dsRNA binding proteins and
are very homologous in their amino acid sequence (Fig. 1).
To determine if PACT and TRBP elicit opposite effects on
PKR’s kinase activity because they interact with PKR
through different residues, we assayed their interaction with
16 point mutants of PKR. We have previously characterized
these mutants with respect to their dsRNA binding and
dimerization activities (Patel and Sen, 1998b; Patel et al.,
1996). Mutants such as A63E and L75E are defective in
protein–protein interaction and show poor dimerization but
have wild-type dsRNA binding affinities. On the other hand,
mutants such as K60A show no detectable dsRNA binding
activity but have significantly enhanced dimerization activ-
ity. We used the coimmunoprecipitation assay to determine
the effect of 16 point mutations on PKR’s ability to interact
with these two proteins. As depicted in Fig. 2, wtPKR
protein could be coimmunoprecipitated with both flag-
PACT (Fig. 2A, lane 4) and flag-TRBP (Fig. 2B, lane 4).
The two mutants F41A and R18G also could be coimmu-
noprecipitated, but with reduced efficiency as compared to
the wt PKR (Figs. 2A and B, lanes 5 and 6). As a negative
control, untagged PKR protein was translated alone, without
any flag-tagged protein (lane 7). As seen in lane 8, no
detectable PKR protein could be precipitated with flag an-
tibody-agarose, thereby confirming the interaction between
flag-PACT and flag-TRBP. Other mutants were assayed in
the same manner, but due to space constraints, we have only
shown representative data for two mutants in Figs. 2A and
B. The amount of [35S]methionine counts in PKR and
PACT in total and IP lanes was quantified by phosphorim-
ager scanning and the percentage interaction was calculated
with respect to the wild-type interaction, which was repre-
sented as 100%. As shown in Fig. 2C, mutants V72Y,
F131A, and K150A showed no effect on the mutation on
PACT and TRBP interactions. F131A and K150A have no
dsRNA binding activity, but show strong interactions with
PACT and TRBP. Mutants R18G, Q19L, Q110L, K154E,
and A158D showed somewhat reduced interaction with
PACT as well as TRBP. Mutants F41A, K60A, A63E,
K64E, A67E, A68D, and L75E showed significant reduc-
tion in interaction with both PACT and TRBP, thereby
indicating the importance of these residues in mediating
their interactions. On the other hand, the mutant K61A
showed significantly enhanced interaction with both PACT
as well as TRBP. From these results, it can be concluded
that PKR-PACT and PKR-TRBP interactions are likely to
be mediated via the same residues within PKR’s two con-
served dsRBMs.
To confirm these in vitro observations, we also per-
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formed in vivo protein interaction assay using the mamma-
lian two-hybrid system originally developed by Fields and
Song (1989). The two proteins, whose interaction is being
tested, are expressed as fusion proteins in mammalian cells.
One protein is fused to the DNA binding domain of the
yeast GAL4 protein and the other is fused to the trans-
activation domain of the VP16 protein of herpes simplex
virus. The two plasmids are cotransfected in cells along with
the reporter plasmid in which the luciferase gene is under
the control of GAL4 binding sites and the synthesis of
luciferase is assayed by measuring its enzyme activity. In
this system, if the two proteins interact, the interaction
brings the VP16 activation domain in close proximity of the
reporter gene promoter and induces transcription of lucif-
erase in a quantitative manner. The amount of luciferase
activity can be directly correlated to the strength of the
interaction between the two proteins. We have previously
used this system successfully to detect and characterize the
PKR dimerization in mammalian cells (Patel and Sen,
1998b; Patel et al., 1996). Here, we assayed the interaction
between VP16-PKR and GAL4-PACT or GAL4-TRBP. As
shown in Fig. 3A, both PACT and TRBP showed a strong
interaction compared to the empty vector controls. The
relative strengths of the interactions between mutant PKR
and PACT (white bars) or TRBP (black bars) were similar
to our results with in vitro coimmunoprecipitation assays. In
addition, there were no differences observed between PACT
and TRBP interactions with mutant PKR. Both proteins
behaved similarly in this assay with respect to PKR inter-
action. However, distinct differences can be identified be-
tween PKR’s interaction with itself (gray bars) and with
PACT/TRBP. F41A, K60A, K64E, K150A, and K154E
mutants showed enhanced PKR dimerization activity pre-
viously (Patel and Sen, 1998b; Patel et al., 1996). However,
these mutants showed significantly reduced interaction with
PACT and TRBP. Similarly, K61A, which showed no sig-
nificant effect on PKR dimerization (Patel et al., 1996),
showed an enhanced interaction with PACT and TRBP.
Differences in expression levels of the interacting proteins
can also lead to the differences in the reporter enzyme
activity. To confirm that the interacting proteins were ex-
pressed at comparable levels in the transfected cells, we
performed Western blot analyses with anti-VP16 and anti-
GAL4 antibodies. As seen in Figs. 3A and B, all proteins
were expressed at uniform levels, thereby confirming that
the luciferase values obtained were a true result of the
relative strengths of these interactions.
Our previous results have shown that the carboxy-termi-
nal motif M3 of PACT (Fig. 4) serves as the activator of
PKR’s kinase activity, and the interaction between PACT
and PKR is mainly mediated via the M1 and M2 motifs of
PACT (Huang et al., 2002; Peters et al., 2001). In addition,
we have also shown that a chimeric protein containing the
M1 and M2 motifs of TRBP fused to the M3 motif of PACT
can activate PKR, thereby strengthening the role of motif
M3 in PKR activation (Huang et al., 2002). These results
suggested that the inhibitory actions of TRBP on PKR may
be mediated via its M3 motif. We therefore created an
expression construct encoding a chimeric protein (Fig. 4A)
that consisted of the M1 and M2 motifs of PACT fused
Fig. 1. Alignment of the conserved dsRNA-binding motifs (dsRBMs) of PACT and TRBP. The three conserved motifs of PACT and TRBP are aligned with
the two motifs of PKR. Darkly shaded residues indicate from the consensus. The consensus is shown below the alignments. Note that the motif 3 from both
proteins are the least homologous and lack the crucial lysines required for dsRNA binding at positions 60, 61, and 64. The numbers on the top indicate the
residue positions corresponding to PKR and the numbers in parentheses represent the same residue positions in motif 2 of PKR. Mutated residues are marked
by asterisks.
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in-frame to the M3 motif of TRBP (P12T3). We confirmed
that the chimeric construct encoded a protein of correct
molecular weight and had corresponding parts of the two
proteins by Western blot analysis (data not shown). We
tested the ability of this protein to activate PKR in an in vivo
translation inhibition assay (Huang et al., 2002; Patel and
Sen, 1998a). Transient overexpression of PACT in mam-
malian cells leads to PKR activation and eIF2 phosphor-
ylation, which can be measured by assaying the expression
of a cotransfected reporter gene such as luciferase. This in
vivo translation repression assay has been used widely by us
and others for PKR activation or inhibition ability of pro-
teins in mammalian cells (Davies et al., 1989; Kaufman et
al., 1989; Kaufman and Murtha, 1987; Park et al., 1994;
Patel et al., 1996; Peters et al., 2001). As shown in Fig. 4B,
cotransfection of wtPKR reduced the luciferase activity
significantly and cotransfection with TRBP showed en-
hanced activity. Cotransfection with a PACT expression
construct and T12P3 also showed reduced luciferase activ-
ity as reported before, although this was not as pronounced
as PKR effect. Cotransfection with the P12T3 expression
construct showed an enhancement of luciferase activity.
These results suggest that a substitution of M3 motif of
PACT with the M3 motif of TRBP leads to an inhibitory
effect on PKR activity. These results were further confirmed
by assaying the effect of recombinant P12T3 protein on in
vitro PKR activity assays. The purity of the recombinant
P12T3 protein was assessed by SDS–PAGE (data not
shown). As seen in Fig. 4C, addition of PACT could acti-
vate PKR activity (lane 4) but addition of P12T3 resulted in
Fig. 2. Interaction of PKR mutants with PACT and TRBP. (A and B) The Flag-epitope tagged, [35S]methionine-labeled PACT (A) or TRBP (B) proteins
were synthesized by cotranslation with untagged wtPKR or mutant PKR proteins using the T7 TNT system. Five microliters of the reticulocyte lysates were
used for coimmunoprecipitation assay using antiflag antibody M2-agarose. The total lanes (lanes 1–3 and 7) represent 2 l of total proteins from the lysate
and the IP lanes (lanes 4–6, and 8) represent coimmunoprecipitated proteins remaining bound to beads after washing. The names of the PKR point mutants
that were cotranslated with PACT/TRBP are indicated at the top of the lanes and the positions of the respective bands are indicated by arrows. The
coimmunoprecipitated PKR bands are also indicated by arrows. Lane 7 represents the negative control where only PKR was translated, without any
flag-tagged protein, and lane 8 shows the immunoprecipitation of this sample. (C) The coimmunoprecipitation gels were quantified by phosphorimager
analysis. The radioactivity present in the bands was measured and the percentage interaction was calculated as 100  (radioactivity present in the
coimmunoprecipitated PKR band/the radioactivity present in the PKR band in the total lane). In addition, this value was normalized to the amount of
radioactivity present in the flag-PACT or flag-TRBP bands to correct for differences in translation/immunoprecipitation steps. The interaction between wtPKR
and TRBP/PACT was taken as 100% and other interactions were normalized with respect to that. The open bars represent PACT and the black bars represent
TRBP. The error bars represent the standard deviation from five independent experiments.
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a dose-dependent inhibition of PKR activity (lanes 2 and 3).
Thus, the PKR activation by PACT and inhibition by TRBP
is mediated via their M3 motifs, and not because their
interaction with PKR is mediated through different residues
within PKR’s dsRBMs.
Discussion
PKR, PACT, and TRBP belong to a family of RNA-
binding proteins that share an evolutionarily conserved
dsRBM (St Johnston et al., 1992). Several proteins belong-
ing to this family have been characterized from E. coli to
human and many of them contain multiple copies of the
conserved motif (Fierro-Monti and Mathews, 2000). De-
spite being highly homologous, PACT and TRBP show
opposite effects on PKR activity. PACT heterodimerizes
with PKR in response to cellular stress and activates it (Ito
et al., 1999; Patel et al., 2000; Peters et al., 2001). On the
other hand, heterodimerization with TRBP results in inhi-
bition of PKR activity (Daher et al., 2001; Park et al., 1994).
Both proteins interact with PKR through its dimerization
Fig. 3. In vivo PACT/TRBP interaction activities of PKR mutants in mammalian two-hybrid system. (A) COS-1 cells were transfected with a mixture four
plasmids: 100 ng VP16 AD-DRBD (wt or point mutants) expression plasmids, 100 ng GAL4 DBD-PACT or GAL4 DBD-TRBP, 800 ng pG5LUC (reporter
plasmid), and 2 ng of pRSV--galactosidase (for normalization of transfection efficiency). Cells were harvested 24 hr after the transfection and assayed for
luciferase and -galactosidase activity. The luciferase values were normalized with the -galactosidase values and the interaction between the wt proteins
was taken as 100% interaction and all other interactions were calculated with respect to that. Gray bars represent interactions between PKR–PKR; white bars
represent interactions between PKR and flag-PACT and black bars represent interactions between PKR and flag-TRBP. The different point mutants of PKR
tested are indicated under the respective bars. (B) Western blot analysis. To ascertain that all the fusion proteins were expressed at comparable levels, 100
g of total protein from cell lysates was analyzed by Western blot analysis with an anti-VP16 activation domain antibody from the PKR–TRBP interaction
set. (C) Western blot analysis. To ascertain that all the fusion proteins were expressed at comparable levels, 100 g of total protein from cell lysates was
analyzed by Western blot analysis with an anti-GAL4 DNA binding domain antibody from the PKR–TRBP interaction set.
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domain, which coincides with its dsRBM. Their interaction
with PKR has been shown to be independent of PKR’s
dsRNA binding activity and point mutants of PKR that are
defective in binding dsRNA show strong interactions with
both PACT and TRBP (Patel et al., 1996 and Fig. 2). PACT
has three copies of the conserved dsRBM and its interaction
with PKR is mediated by its two amino-terminal copies
(Huang et al., 2002; Peters et al., 2001). The third copy of
the conserved motif is not involved in mediating the inter-
action. It also lacks certain conserved, basic residues that
are crucial for dsRNA binding and is therefore devoid of
any detectable dsRNA-binding activity. However, this third,
carboxy-terminal domain is essential for activation of PKR
and a deletion of this domain leads to a total loss of PKR
activation (Huang et al., 2002; Peters et al., 2001).
Here, we have investigated the effect of point mutants in
PKR’s dimerization/dsRBM on its interaction with PACT
and TRBP. Our results indicate that PACT and TRBP in-
teract with PKR through the same residues within the
dimerization domain and that their opposite actions are
mediated by the carboxy-terminal third conserved domains,
which are also the most divergent. PACT and TRBP differ
in their dsRNA-binding activities. The motifs M1 and M2 of
PACT show strong interaction with dsRNA, whereas the
motif M3 shows no detectable dsRNA binding. In the case
of TRBP, the motifs M1 and M3 show no dsRNA binding
and the dsRNA binding of TRBP is mainly mediated
through its motif M2 (Daher et al., 2001). However, both
M1 and M2 motifs of TRBP direct its heterodimerization
with PKR (Daher et al., 2001), thereby indicating that motif
M2 can mediate interaction with PKR, despite its lack of
dsRNA binding.
Although the point mutations affected the PACT-PKR
and TRBP-PKR interactions in a similar manner, we did
observe significant differences with respect to their effect on
PKR–PKR interactions. Mutations such as F41A, K60A,
K64E, K150A, and K154E did not affect the PKR–PKR
interaction but were deleterious for PACT–PKR and TRB-
P–PKR interactions. K61A mutation did not affect the
PKR–PKR interaction but showed enhanced interaction
with PACT and TRBP. Several mutations such as A63E,
A67E, A68D, L75E, and A158D were deleterious to all
three interactions. These results suggest that the interactions
mediated by different dsRBM motifs may be dependent on
different residues in the interacting partners. In this regard,
PACT–PKR and TRBP–PKR interactions are mediated by
similar residues in PKR’s dsRBMs, but the PKR–PKR
interaction occurs via an overlapping but different set of
residues.
The domain swap experiments indicated that the PKR
activation ability of PACT was lost when the carboxy-
terminal motif M3 of PACT was substituted with the cor-
responding motif M3 of TRBP (Huang et al., 2002). Simi-
larly, the PKR-inhibitory activity of TRBP was lost when
motif M3 of TRBP was substituted with the corresponding
motif M3 from PACT. These results indicate that TRBP and
Fig. 4. The P12T3 chimeric protein inhibits PKR activity in vivo and in
vitro. (A) A schematic representation of the various chimeric proteins. The
hatched boxes represent the three conserved motifs M1, M2, and M3 in
PACT. The white boxes represent the corresponding conserved motifs in
TRBP. The gray box represents PACT sequences outside of its conserved
motifs and the black boxes represent TRBP sequences outside of its
conserved motifs. (B) PKR activation activity of the chimeric proteins in
vivo. Translation inhibition assay was performed in the MEF cells grown
in six-well plates. The reporter used was pGL2C. Eight hundred nono-
grams of pGL2C was cotransfected using Lipofectamine reagent with 200
ng of the expression constructs for the protein indicated under the bars.
Twenty-four hours after the transfection, the cells were treated with 100
U/ml of IFN for 24 h and luciferase activity was measured in the cell
extracts and normalized to the total protein in the extract. All expression
constructs were in pCB6. “Vector” indicates empty vector (pCB6)
control. Each sample was assayed in triplicate and the bars represent an
average of six samples from two separate experiments. The error bars
indicate standard deviation. (C) P12T3 protein inhibits PKR activity in a
dose-dependent manner. Effect of purified recombinant P12T3 protein
added to PKR kinase activity assays was studied. Lane 1: no activator
added; lane 2–3: 0.25, and 0.5 pmol of pure recombinant P12T3 protein
added, respectively; lane 4: 0.116 pmol of pure recombinant PACT. The
positions of phosphorylated PKR and eIF2 are indicated by arrows.
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PACT’s opposing actions on PKR activity mainly result
from differences in their carboxy-terminal motif M3 and the
two proteins interact with PKR through the same residues
within PKR’s dsRBMs. These results raise an interesting
question about the ability of an dsRBM to activate PKR.
The third dsRBMs of both PACT and TRBP do not exhibit
any dsRNA binding activity and also are the least homolo-
gous among the three dsRBMs of PACT and TRBP. In
addition to the sequence differences, the spacing between
the M2 and M3 domains is different in PACT and TRBP.
TRBP has a significantly longer spacer between M2 and
M3. We know that the spacer region between M2 and M3 of
PACT is not essential to PKR activation, since the recom-
binant M3 domain by itself can activate PKR in vitro and
interacts directly albeit transiently with PKR’s catalytic
domain (Huang et al., 2002). The recombinant M3 domain
of TRBP showed no effect on PKR activity in vitro (data not
shown), thereby indicating that unlike PACT’s M3 domain,
it lacks the PKR interaction and activation ability. Future
experiments with reduced spacing between M3 domain of
TRBP in the P12T3 construct and additional point mutants
within M3 domains of PACT and TRBP can indicate the
importance of spacing and/or crucial residues essential for
PKR activation.
The dsRBMs have been found in proteins from several
diverse sources, such as bacteria, lower and higher eu-
karyotes, and viruses (Fierro-Monti and Mathews, 2000; St
Johnston et al., 1992). Most of these dsRNA binding pro-
teins contain multiple dsRBMs. Several proteins belonging
to this class have been described as PKR-interacting pro-
teins including PACT, TRBP, NF90 (Langland et al., 1999;
Parker et al., 2001; Patel et al., 1999), and p74 (Coolidge
and Patton, 2000). However, the cellular functions of many
other proteins in this family remain unknown. Since the
conserved motif directs both homo- and heterodimerization
between this class of proteins, it remains to be examined if
such interactions can be regulatory as in the case of TRBP–
PKR and PACT–PKR.
Materials and methods
In vitro protein–protein interaction assays
35S-labeled PKR and flag epitope-tagged PACT protein
or TRBP protein were cotranslated using the TNT T7 cou-
pled reticulocyte system from Promega. Five microliters of
the in vitro translated 35S-labeled proteins was incubated
with 20 l of anti-flag mAb-agarose (Sigma) in 200 l of IP
buffer [20 mM Tris–HCl pH 7.5, 100 mM KCl, 1 mM
EDTA, 1 mM dithiothreitol (DTT), 100 U/ml aprotinin, 0.2
mM phenylmethylsulfonyl fluoride (PMSF), 20% glycerol,
1% Triton X-100] at 4°C for 30 min on a rotating wheel.
The beads were washed in 500 l of IP buffer four times
and the washed beads were then boiled in 2 Laemmli
buffer (150 mM Tris–HCl pH 6.8, 5% SDS, 5% -mercap-
toethanol, 20% glycerol) for 2 min and eluted proteins were
analyzed by SDS–PAGE on a 12% gel. The dried gels were
analyzed by phosphorimager analysis. The percentage in-
teraction was calculated based on input counts and immu-
noprecipitated counts of the PKR bands. The amounts were
normalized not only to the input counts, but also to the total
amount of flag-PACT or flag-TRBP that was immunopre-
cipitated. The interaction between the wtPKR and TRBP/
PACT was taken as 100% and all other interactions were
represented with respect to that.
In vivo protein–protein interaction assays
The in vivo interaction between the various point mu-
tants of PKR and PACT or TRBP was assayed using the
mammalian two-hybrid system as described before (Patel
and Sen, 1998a,b; Patel et al., 1995, 1996). The DRBD
portions of the various point mutants were amplified previ-
ously by PCR and subcloned into pVP16AASV19N
(Takacs et al., 1993). These constructs express the DRBDs
as a VP16 activation domain (AD) fusion protein and are
tested for interaction with a GAL4 DNA-binding domain
(DBD) fusion of PACT or TRBP. COS-1 cells were trans-
fected with 200 ng of each of the four (two test plasmids
encoding proteins to be tested for interaction, the reporter
plasmid pG5Luc, and plasmid pRSV--galactosidase to
normalize transfection efficiency) plasmid DNAs by the
Lipofectamine (Invitrogen) procedure. Cells were harvested
48 h after transfection and assayed for luciferase activity
after normalization for transfection efficiency by measuring
-galactosidase activity.
Construction of domain swap mutants P12T3 and T12P3
The construction of P12T3 has been described before
(Huang et al., 2002). P12T3 construct was created to encode
the amino acids 1–196 of PACT fused to the amino acids
200–345 of TRBP. The resulting chimeric P12T3 protein is
342 amino acids long. The fusion construct was created by
PCR amplification of the relevant TRBP region. The EcoRI
site in PACT coding region was used to fuse the PCR
product in-frame to PACT by designing the EcoRI site
within the upstream PCR primer. The resulting chimeric
cDNA was confirmed by sequencing and subcloned into
eukaryotic expression vector pCB6 and a flag epitope tag
was introduced at the amino-terminal end of the protein to
monitor expression. The chimeric cDNA was also sub-
cloned into prokaryotic expression vector pET15b (Nova-
gen). The recombinant P12T3 protein was expressed and
purified from E. coli as described before (Huang et al.,
2002).
Translation inhibition assays
The effects of PACT and TRBP and their mutants were
tested using the translation inhibition assay as described
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before. In this assay, the effect of cotransfection with an
effector plasmid is tested on translation of a reporter such as
luciferase. MEF cells were transfected in six-well plates in
triplicate with 800 ng of pGL2C reporter plasmid and 200
ng of effector plasmid (expression constructs of flag-PACT,
flag-TRBP, flag-P12T3, and flag-T12P3) DNAs using the
Lipofectamine reagent. At 24 h after transfection, the cells
were treated with 100 U/ml of IFN-. Cells were harvested
48 h after transfection and assayed for luciferase activity.
PKR activity assay
PKR activity assays were performed as described before
(Patel et al., 2000, 2002; Patel and Sen, 1998a) using anti-
PKR monoclonal antibody (Ribogene, 71/10 monoclonal).
HeLa M cells were maintained in DMEM with 10% FCS.
The cells were harvested when they were at 70% conflu-
ency. Cells were washed in ice-cold phosphate-buffered
saline (PBS) and packed by centrifugation at 600g for 5
min. They were lysed by addition of an equal volume of
lysis buffer (20 mM Tris–HCl pH 7.5, 5 mM MgCl2, 50 mM
KCl, 400 mM NaCl, 2 mM DTT, 1% Triton X-100, 100
U/ml aprotinin, 0.2 mM PMSF, 20% glycerol). The lysates
were centrifuged at 10,000g for 5 min and the supernatants
were assayed for PKR activity. A 100-g aliquot of total
protein was immunoprecipitated using PKR monoclonal
antibody (71/10) in the high salt buffer (20 mM Tris–HCl
pH 7.5, 50 mM KCl, 400 mM NaCl, 1 mM EDTA, 1 mM
DTT, 100 U/ml aprotinin, 0.2 mM PMSF, 20% glycerol,
1% Triton X-100) at 4°C for 30 min on a rotating wheel.
Then 10 l of protein A–Sepharose slurry was added and
incubation was carried out for a further 1 h. The protein
A–Sepharose beads were washed in 500 l of high salt
buffer four times and twice in activity buffer (20 mM
Tris–HCl pH 7.5, 50 mM KCl, 2 mM MgCl2, 2mM MnCl2,
100 U/ml aprotinin, 0.1 mM PMSF, 5% glycerol). PKR
assay was performed with PKR still attached to the beads in
activity buffer containing 250 ng of purified eIF-2 (kindly
provided by Dr. William Merrick, Case Western Reserve
University), 0.1 mM ATP, and 1 Ci of [-32P]ATP at 30°C
for 10 min poly(I)-poly(C) (0.1 g/ml) or 0.116 pmol of
pure PACT protein was used as the standard activator for
the enzyme. Purified P12T3 in amounts 0.115 and 115 pmol
were added to test its effect on PKR activity. Labeled
proteins were analyzed by SDS–PAGE on a 12% gel fol-
lowed by autoradiography.
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